At 52 weeks, the 30-mg daily oral dose of brepocitinib outperformed the 15-mg dose in a study of patients with dermatomyositis resistant to previous treatments.

A subgroup analysis of the VASALIUS-CV trial showed evolocumab significantly cut LDL cholesterol and cardiovascular event risk in people with diabetes but no known atherosclerosis.

The landscape of topical therapies for melasma is evolving quickly as a steady stream of new agents becomes available, offering alternatives to traditional frontline strategies, a dermatologist told ...

The trial of percutaneous left atrial appendage closure vs direct oral anticoagulants in patients with AF is called positive, ...

CHAMPION-AF finds left atrial appendage closure and anticoagulation therapy for atrial fibrillation about equal but raises doubts about whether the former is a true alternative.

A population-based, prospective cohort study conducted in China finds that lung cancer risk remains low until 3 years after a negative low-dose CT screen.

Elinzanetant reduces the severity and frequency of hot flushes and night sweats among women with breast cancer regardless of ...

In patients with GERD, dominant symptom intensity is a simple patient-reported measure that identifies the most burdensome ...

Vall d’Hebron reorganized care into Knowledge Areas; the Heart Area pilot cut length of stay by 18%, 30-day readmissions by ...

New data confirm similar response rates with fewer toxicities when carboplatin is dropped from standard neoadjuvant therapy in early HER2-positive breast cancer.

A chest-worn biosensor that features several measurement signals in one device reliably identifies the presence and severity ...